Weight management, metabolic health, glucose regulation
GLP-1 (Semaglutide)
Semaglutide is a long-acting GLP-1 receptor agonist used in approved medications for type 2 diabetes and weight management. It influences appetite, gastric emptying, insulin secretion, glucagon signaling, and blood-glucose regulation.
Administration Reference
Subcutaneous
Dose Information
0.25 mg starting dose, titrated gradually up to 2.4 mg weekly
Frequency
Once weekly
Duration / Cycle
Ongoing; no fixed cycle length
Storage Guidance
Refrigerate after reconstitution and use within about 30 days, Freeze in lyophylized powder form
Supplies
Affiliate disclosure: We may earn a commission if you purchase through these links.
Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.
Syringes & transfer supplies
EasyTouch U-100 Insulin Syringes (31G 0.5cc 5/16″) – 100ct.U-100 Insulin Syringes (31G 0.5cc 5/16") – 100ctInsulin syringes – Polybag, 50 Unit Capacity, 5/16” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →
Protective supplies & disposal
MED PRIDE Sterile Alcohol Prep Pads1 BOX OF 200INDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 1 BOX OF 200, MEDIUM SIZE PREP PADSView at AMAZON →
Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →
Square Sharps Container, 2 QuartQTY 1View at AMAZON →
Commonly Reported Uses
Semaglutide (Ozempic, Wegovy, Rybelsus), is primarily known for weight management; appetite reduction; type 2 diabetes management; blood-glucose control; cardiovascular risk reduction in selected populations; metabolic-health improvement.
Commonly Reported Indicators
Reduced hunger and food cravings, greater satiety, progressive weight loss, and improvement in glucose-related markers such as HbA1c.
Mechanism Overview
Semaglutide activates GLP-1 receptors in the brain, pancreas, and gastrointestinal system. This enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake.
Safety
Safety Considerations
Gastrointestinal effects are the most frequently reported tolerability issue. More serious concerns discussed on the source page include pancreatitis, gallbladder complications, delayed gastric emptying, severe dehydration, kidney problems, diabetic-retinopathy progression, allergic reactions, and hypoglycemia when combined with certain glucose-lowering medications.
Reported Adverse Effects
Nausea, constipation, diarrhea, reduced appetite, fatigue, vomiting, and other gastrointestinal symptoms.
Contraindications & Cautions
Personal or family history of medullary thyroid carcinoma; MEN 2; pregnancy or breastfeeding; history of pancreatitis; additional caution with insulin or sulfonylureas and in people with diabetic retinopathy.
Status
Regulatory Status
Semaglutide is FDA approved in prescription formulations for approved indications including type 2 diabetes and chronic weight management.
Development / Research Status
Approved medication
Market Classification
Prescription medication
Status Notes
FDA-approved prescription semaglutide should be distinguished from products marketed separately as research-use compounds; research labeling does not make those products approved for human use.
Research & Evidence
Evidence Level
Approved clinical use
Research Last Reviewed
2026-09-05
Research Overview
Semaglutide has extensive human clinical evidence covering obesity, type 2 diabetes, cardiovascular outcomes, and oral and injectable formulations. The source highlights the SELECT, SUSTAIN, STEP, STEP TEENS, and PIONEER clinical programs.
Human Research
SELECT enrolled 17,604 adults with cardiovascular disease and overweight or obesity without diabetes; weekly 2.4 mg semaglutide reduced major cardiovascular events versus placebo. STEP 5 demonstrated sustained weight reduction through 104 weeks. PIONEER established efficacy and safety of oral semaglutide, while STEP TEENS demonstrated substantial BMI reduction in adolescents with obesity.
In Vitro Research
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — PMID 37952131; DOI 10.1056/NEJMoa2307563
SUSTAIN Diabetes Program — PMID 30615985
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial — PMID 36216945
PIONEER 1 — PMID 31186300
STEP 1 Trial — PMID 33567185
Once-Weekly Semaglutide in Adolescents with Obesity — PMID 36322838